Avalo Therapeutics CSO Jennifer Riley Sells 588 Shares at $13.10

Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, filed a Form 4 disclosing the sale of 588 shares of common stock on June 10, 2026, at a price of $13.10 per share. The transaction was executed under Rule 10b5-1, indicating it was part of a predetermined trading plan. Following the sale, Riley owns 39,696 shares of common stock, which includes 3,429 shares acquired through the company's Employee Stock Purchase Plan. The filing represents a routine insider transaction that provides transparency about executive stock ownership changes at the biopharmaceutical company.